BioCardia (BCDA) Stock: Buy, Sell, or Hold?
BCDA - BioCardia, Inc. Common Stock
$1.08
-0.02 (-1.82%)
âŧ
5d:
-0.92%
30d:
+22.73%
90d:
+35.83%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When BCDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BCDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BCDA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BCDA is currently trading at $1.08, which is considered fair relative to its 30-day fair value range of $0.95 to $1.12.
Technical Outlook: Technically, BCDA is showing sideways momentum. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCDA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+1335.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCDA is showing sideways momentum. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCDA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.50 (+1335.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.95 -
$1.12
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1335.2% below Wall St target ($15.50)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.95 -
$1.12
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.20
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.86
Wall Street Target
$15.50
(+1335.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 13, 2026 1:40 AM ET
Data refreshes hourly during market hours. Next update: 2:40 AM
Data refreshes hourly during market hours. Next update: 2:40 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCDA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Altman
BUY
400 shares
2026-04-21
Peter Altman
BUY
600 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |